Last Published:  07/30/20 02:45:15 PM (Central)
Short Title: CBS Data Mining CMs: Fam Hist/Prev Med/Individual Sensitivities/Exposures/Monitoring Exposures
Responsible HRP Element: Human Factors and Behavioral Performance
Collaborating Org(s):
Human Health Countermeasures (HHC) Element
Other:
Space Radiation (SR) Element
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Directed
Aims:

Robust identification of current research that identifies both pre-mission risks and vulnerabilities for individuals due to family history, previous exposures, preventive medicine, sensitivites, genotype and phenotype within the context of integrated risk and risks posed to crew health and safety and the countermeaaures needed should medical conditions arise.  For example, in major depressive disorder, high levels of histone deacetylase 5 prior to treatment initiation appear to be a robust marker for treatment response (Iga et al., 2007; Hobara et al., 2010; Belzeaux et al., 2010). Levels of cyclic-adenosine monophosphate (cAMP) response element binding protein 1 (Iga et al., 2007), histone deacetylase 2 (Hobara et al., 2010), serotonergic markers (Belzeaux et al., 2010), a panel of four gene expression pro les (Belzeaux et al., 2012), and interferon regulatory factor 7 (Mamdani et al., 2011) have variously been reported to change following treatment with antidepressants.

-Belzeaux R, Formisano-Tre´ziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Fe´ron F, Naudin J, Ibrahim EC (2010) Clinical variations modulate patterns of gene expression and de ne blood biomarkers in major depression. J Psychiatr Res 44:1205–1213.
-Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC (2012) Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185.
-Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suetsugi M, Watanabe Y (2010) Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 44:263–270.
-Iga Ji, Ueno Si, Yamauchi K, Numata S, Kinouchi S, Tayoshi- Shibuya S, Song H, Ohmori T (2007) Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 31:628–632.
-Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C, Turecki G (2011) Gene expression biomarkers of response to citalo- pram treatment in major depressive disorder. Transl Psychiatry 1:e13.

Resources (None Listed)
Mappings
RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
GapBMed-101: We need to identify, quantify, and validate the key selection factors for astronaut cognitive and behavioral strengths (e.g., resiliency) and operationally-relevant performance threats for increasingly Earth independent, long-duration, autonomous, and/or long-distance exploration missions.
GapBMed-102: Given exposures to spaceflight hazards (space radiation, isolation), how do we identify individual susceptibility, monitor molecular/biomarkers and acceptable thresholds, and validate behavioral health and CNS/neurological/neuropsychological performance measures and domains of relevance to exploration class missions?
GapBMed-103: What are the validated, efficacious treatments (individual or Team-based) and/or countermeasures to prevent adverse behavioral conditions, CNS/neurological, and/or psychiatric disorders caused by either single and/or integrated exposures to spaceflight hazards during exploration class missions?
GapBMed-104: Given the potentially negative spaceflight associated CNS changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated modifications to habitat/vehicle to mitigate stressors impacting on CNS / cognition / behavioral health?
GapBMed-105: Given the potentially negative spaceflight associated CNS/cognitive changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated medical or dietary countermeasures to mitigate stressors impacting on CNS / cognition / behavioral health?
GapBMed-107: What are the long-term changes and risks to astronaut health post-mission that, when using a continuity of care model, helps retrospectively identify and understand individual susceptibility (e.g., hereditary, dose, thresholds) to mitigate adverse CNS, cognitive, and behavioral health changes resulting from long-duration exploration missions, promoting the behavioral health of current and future crews?
GapBMed-108: Given each crewmember will experience multiple spaceflight hazards simultaneously, we need to identify and characterize the potential additive, antagonistic, or synergistic impacts of multiple stressors (e.g., space radiation, altered gravity, isolation, altered immune, altered sleep) on crew health and/or CNS/ cognitive functioning to develop threshold limits and validate countermeasures for any identified adverse crew health and/or operationally-relevant performance outcomes.
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures

RiskRisk of Impaired Control of Spacecraft/Associated Systems and Decreased Mobility Due to Vestibular/Sensorimotor Alterations Associated with Spaceflight
You are here!TaskIntegrative Risk Data Mining: Individual Sensitivities and Countermeasures